CANF data due by end of March. IMMU lupus data due 1H + pipeline updates for GWPH BIND IRWD MSTX

Feb 05, 2015 No Comments by

Latest updates to the Company Pipeline Database for February 4, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated BIND 6.34 BIND-014 Cancer – KRAS mutant Non-small cell lung cancer (NSCLC) Phase 2 Preliminary data due 2H 2015 2/5/2015 BIND 6.34 BIND-014 Cancer – Squamous histology NSCLC […]

Daily News Read more


Nov 08, 2014 No Comments by

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Phase 2 data lock of NSI-566 spinal cord-derived stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS) is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase 2 ALS results. The company also noted that a Phase 2 trial of NSI-189 for […]

Daily News Read more

ECYT Phase 3 trial halted + pipeline updates for ACOR MACK TRVN ITMN NBY VTL

May 04, 2014 No Comments by

Merck (NYSE:MRK) and Endocyte, Inc. (NASDAQ:ECYT) announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of Progression-Free Survival (PFS) in patients with platinum-resistant ovarian cancer. Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that the FDA has issued […]

Daily News Read more

ICPT wows the biotech world. ITMN Ph3 data due early 2Q. IMMU initiates Ph3 pancreatic trial + SNTA AEGR BOTA XLRN news

Jan 10, 2014 No Comments

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT $257.87) announced that the Phase 2 FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. They also noted that data from their Phase 3 POISE trial of obeticholic […]

Read more

CPRX receives Breakthrough Designation. RIGL fails Phase 2 trial. OREX NDA due end of 2013 + updates for SGMO QRXPY OGXI ONXX AMGN IMMU

Aug 28, 2013 No Comments

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX $2.01)  announced that Firdapse, currently in Phase 3 development, has received “Breakthrough Therapy Designation” by the FDA for the treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL $3.11) announced that R343, for patients with allergic asthma, did not meet the primary or secondary endpoints in a Phase 2 […]

Read more

Pipeline updates for YMI OREX IMMU BDSI FOLD

May 11, 2012 No Comments

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) provided an update today on CYT387 for the treatment of myelofibrosis. It intends to initiate its Phase 3 trial during 2H 2012. By the end of 2012 both final data from its Phase 1/2 Core trial and interim data from the Phase 1/2 Extension trial are expected to be reported. Interim […]

Read more

NBIX VICL EXEL IMMU CRIS pipeline updates + numerous companies raising cash

Feb 09, 2012 No Comments

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) gave a pipeline update today noting that it expects to initiate its Phase 3 trial of elagolix for endometriosis during 1H 2012. It also expects data from its second Phase 2 trial of NBI-98854 in tardive dyskinesia patients during March 2012. A larger Phase 2b program is planned to be initiated during 2012. Topline data […]

Read more

ALXA panel vote.YMI CYT387 data + PCYC CYTR IMMU GERN NKTR OPTR news

Dec 12, 2011 No Comments

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) appeared before the Psychopharmacologic Drugs Advisory Committee (PDAC) today where the committee was divided on whether Adasuve should be approved as a single dose when used with FDA proposed REMS, with 9 votes FOR, 8 votes AGAINST and one abstention. It had earlier voted that Adasuve had been shown to be effective […]

Read more


Nov 05, 2011 No Comments

Inhibitex, Inc. (NASDAQ:INHX) today reported top-line safety and antiviral data from the first cohort of its ongoing clinical trial of INX-189, for HCV. In this study, 200 mg INX-189, dosed once-daily for seven days, continued to demonstrate potent and dose-dependent antiviral activity with a median HCV RNA reduction from baseline of -4.25 log10 IU-mL. Further, […]

Read more

YMI pipeline update. OPTR positive CHMP opinion. IMMU clinical hold + RGRX CYCC

Sep 09, 2011 No Comments

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea (CDAD). RegeneRx Biopharmaceuticals, Inc. (OTC […]

Read more

IMMU pipeline update. PPHM Ph2 breast cancer data. ZGNX to raise cash

Aug 24, 2011 No Comments

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced 20.7 month median overall survival (OS) from a prior single-arm Phase 2 trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. Immunomedics, Inc. (Nasdaq:IMMU) gave a pipeline update today saying that it intends to initiate a Phase 3 trial in 2012 […]

Read more